Chan 2002.
Methods | 3‐Week wash‐out period 6‐Week single‐centre randomised double‐blind placebo‐controlled study Evening doses | |
Participants | 25 obese men from Australia recruited from the community with dyslipidaemia, mean age 52 years; TG > 1.2 mmol/L (106 mg/dL), TC > 5.2 mmol/L (201 mg/dL) 12 participants received placebo, 13 received atorvastatin Exclusion criteria: diabetes E2/E2 genotype, macroproteinuria; liver, renal dysfunction; hypothyroidism, CVD, > 30 g alcohol/d Placebo baseline TC: 5.82 mmol/L (225 mg/dL) Placebo baseline LDL‐C: 3.80 mmol/L (147 mg/dL) Placebo baseline HDL‐C: 1.05 mmol/L (41 mg/dL) Placebo baseline TG: 1.69 mmol/L (150 mg/dL) Atorvastatin baseline TC: 5.81 mmol/L (225 mg/dL) Atorvastatin baseline LDL‐C: 3.81 mmol/L (147 mg/dL) Atorvastatin baseline HDL‐C: 1.01 mmol/L (39 mg/dL) Atorvastatin baseline TG: 1.88 mmol/L (167 mg/dL) |
|
Interventions | Placebo Atorvastatin 40 mg/d |
|
Outcomes | Per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C and TG | |
Notes | SDs were imputed WDAEs were not reported |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No information about sequence generation was provided to permit judgement of 'yes' or 'no' |
Allocation concealment (selection bias) | Unclear risk | No information about allocation concealment was provided to permit judgement of 'yes' or 'no' |
Blinding (performance bias and detection bias) All outcomes | Low risk | "Double‐blind, placebo‐controlled intervention" |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Data on all participants were reported |
Selective reporting (reporting bias) | High risk | All lipid parameters were measured; withdrawals due to adverse events were not reported |
Other bias | High risk | Pfizer partially funded the study; data may support bias for atorvastatin |